SCOTTSDALE, Ariz. - Health Enhancement Products, Inc. (OTCBB:HEPI - News) was given a “Notice of Allowance” by the U.S. Patent & Trademark Office, after which a formal notice of patent issuance will follow. Once issued the patent will provide intellectual property protection for the Company’s proprietary algae extract, specifically as it applies to addressing a wide range of conditions and illnesses.

“This is a critical milestone for our Company as we build a solid body of nutritional science that will allow us to enter the food ingredient and nutraceutical industry with new credible and effective natural products,” says John Gorman, HEPI’s Director and board member. “We will be providing more detail at the June 8 press event in New York City at the New York Athletic Club.”

“The algae extract is shown to be effective when taken orally administered in liquid form and is stable, not easily degraded and maintains bioactivity in air as well as at room temperature,” notes HEPI Chief Scientific Officer, Denis Callewaert, PhD. “These are unique and ideal characteristics for a successful food ingredient.”

HEPI will host a scientific panel in New York at noon on Tuesday, June 8, 2010 at the New York Athletic Club with Dr. Smiti Gupta, assistant professor of nutrition and food sciences at Wayne State University and principal investigator of the cholesterol study. Other scientists presenting will include Dr. Fazlul Sarkar, Dr. Denis Callewaert, and Dr. Donald Armstrong.

About Health Enhancement Products, Inc.

Health Enhancement Products, Inc. (OTCBB:HEPI - News) is a health & wellness company engaged in the development of products comprised of pure, all-natural compounds that can be used as a dietary supplement and food additive. The Company's product is ProAlgaZyme® (PAZ™), a liquid product drawn from living algae grown in purified water. The water in which the algae are grown is drawn off, filtered and bottled under the trademark ProAlgaZyme®.

---

100% Natural Products for Total Body Health, The Way Nature Intended.

Health Enhancement Products, Inc. (HEPI) is directed specifically at the selection and marketing of only the best of natural and herbal products including ProAlgaZyme.

This direction arises from our convictions that:

• the body is the strongest healing force known to mankind
• proper diet, exercise, and medication are the best means of keeping the human body’s healing powers at their best
• the best medication is that which comes from natural sources, and which protect the body from harmful side-effects.

It is the mission of Health Enhancement Products, Inc. to develop health through science, products that are:

• natural or derived from naturally-occurring materials -- without reliance on synthetics;
• based on all-natural herbal extracts and botanical derivatives;
• sold as foods and dietary supplements to promote wellness;
• of premium quality.

With this primary mission, the Company will continue to seek products to either create and fulfill a marketing opportunity, offering substantial value for price, and which encourage customers to continue to enjoy good health through science.

The Company pursues multi-faceted research into health issues relevant to its products, and supports on-going clinical and academic research efforts wherever practicable.

The Company will also act with full responsibility to its investors and shareholders, and will seek opportunities consistent with the goals set above, to maximize shareholder benefit and deliver improved health through science.

* The FDA has not evaluated these statements. ProAlgaZyme is not intended to diagnose, treat, cure or prevent any disease.

---

ProAlagaZyme - Product Brochure

---

HEPI is focused on isolating and identifying the active cholesterol agents present in PAZ. A study conducted during summer 2009 at Wayne State University’s Department of Nutrition and Food Science by Dr. Smiti Gupta demonstrated unequivocally that PAZ filtrates are able to lower LDL cholesterol while raising HDL cholesterol in animal subjects.

This bolsters previous studies that indicated similar results in humans and animals, albeit not under the strict conditions imposed by the  Wayne State University study. Full report http://www.heponline.com/docs/paz_waynest_cholest.pdf

Background

Metabolic Syndrome, or Syndrome X, is characterized by a set of metabolic and lipid imbalances that greatly increases the risk of developing diabetes and cardiovascular disease. The syndrome is highly prevalent in the United States and worldwide, and treatments are in high demand. ProAlgaZyme, a novel and proprietary freshwater algae infusion in purified water, has been the subject of several animal studies and has demonstrated low toxicity even with chronic administration at elevated doses. The infusion has been used historically for the treatment of several inflammatory and immune disorders in humans and is considered well-tolerated. Here, the infusion is evaluated for its effects on the cardiovascular risk factors present in metabolic syndrome in a randomized double-blind placebo-controlled study involving 60 overweight and obese persons, ages 25–60. All participants received four daily oral doses (1 fl oz) of ProAlgaZyme (N = 22) or water placebo (N = 30) for a total of 10 weeks, and were encouraged to maintain their normal levels of physical activity. Blood sampling and anthropometric measurements were taken at the beginning of the study period and after 4, 8 and 10 weeks of treatment. Eight participants did not complete the study.

Results

ProAlgaZyme brought about statistically significant (p < 0.001) reductions in the following: weight, body fat, total cholesterol, LDL-cholesterol, triglycerides, C-reactive protein and fasting blood glucose levels, accompanied by a significant (p < 0.001) increase in HDL-cholesterol levels over the 10-week study period. The infusion was well-tolerated and no side effects were noted.

Conclusion

ProAlgaZyme (4 fl oz daily) consumption resulted in significant reductions in weight and blood glucose levels, while significantly improving serum lipid profiles and reducing markers of inflammation, thus improving cardiovascular risk factors in overweight and obese subjects over a course of 10 weeks with an absence of adverse side effects.

---

Lipids in Health and Disease

Trial Registration

US ClinicalTrials.gov NCT00489333

Full article http://www.lipidworld.com/content/6/1/20

Health Enhancement Products, Inc. will feature a live panel presentation, conference call and simultaneous webcast. Interested parties can attend in person or view the webcast at http://www.visualwebcaster.com/event.asp?id=69592. Webcast participants will need to register prior to the event.

Health Enhancement Products, Inc. was formed in 2003 specifically to address the selection and marketing of a variety of health- enhancing products which are:

• natural – that is, they contain all-natural herbal or botanical extracts and they do not contain manufactured chemicals or medicines;
   
• intended to provide the body with the resources to heal itself through fully natural processes;
   
• delivered and marketed as foods and dietary supplements.

Intellectual Property Position - HEPI has patents pending covering the following:

"Method of Preparation and Use of Fibrinolytic Enzymes in the Treatment of Disease"

1. an efficient and novel process for producing phyto-percolates.
2. use of the novel compositions from above in treating humans and mammals.

"Composition and Use of Aquatic Organism Metabolites in the Treatment of Disease"

1. new compositions derived from aquatic organism secretions.
2. use of the novel compositions from above in treating humans and mammals.

The Company is located in Scottsdale, AZ where it maintains a production center for its ProAlgaZyme™ product, and from which it administers the production and distribution of its other products.

Stock Trading Information:
HEPI commenced public trading in November 2003, and currently trades on the over-the-counter Bulletin Board under the symbol HEPI.

Present corporate planning centers around:

1. Operation of a secure production facility for growing, harvesting and processing marketable quantities of ProAlgaZyme™.
    
2. Launch of products. The Company is currently engaged in launching new products. In addition, we are conducting negotiations with several major distributors in the foods and dietary herbal supplements industries, and anticipate that the commitment of at least one of these groups will immediately provide an effective release volume and early profitability.

Latest Hepi Press Releases: http://www.heponline.com/press.html